Adrenocortical Carcinoma Treatment Market Research Forecast, Regional, Trends and Analysis to 2023

Adrenocortical Carcinoma Treatment Market will expand at a CAGR of 8.4% through 2024.

Adrenocortical carcinoma (ACC) is a rare and highly aggressive carcinoma. According to the US National Library of Medicine, the overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 months. The rising incidence rate, a rise in the number of drugs in clinical trials for specific chemotherapeutics, and the increase in risk-factors are anticipated to drive the growth of the market during the assessment period. According to the International Pediatric Adrenocortical Tumor Registry, the female-to-male ratio for adrenocortical carcinoma is approximately 2.5-3:1. Inherited disorders such as Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syndrome (BWS), and Carney complex are linked with increased incidences of adrenocortical carcinoma. According to the survey by Endocrine Society, 2014, adrenocortical carcinoma comprises an approximate 3% to 10% of malignancies in LFS and over 5-15% of malignancies in BWS.  However, differentiation of benign and malignant tumor in the initial stages needs proper evaluation. The pathohistological diagnosis also remains challenging.  These factors coupled with the lack of oncology experts may restrain the growth of the market during the forecast period.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/6567 

On a regional basis, the adrenocortical carcinoma treatment market in the Americas is anticipated to dominate the market during the forecast period. The market growth in this region is owing to the advanced healthcare expenditure and advancements in medical device technologies. Moreover, higher demand for quality products and the availability of reimbursement policies are expected to contribute to the market growth in this region.

Currently, the global adrenocortical carcinoma treatment market is dominated by several players. The prominent players in this market are involved in new product launches, strategic partnerships to expand their product portfolio.  For instance, in April 2015, ArQule, Inc. announced ARQ 087 is currently in a Phase 2 trial in patients with Intrahepatic Cholangiocarcinoma (ICC) with FGFR2 fusions and a Phase 1b trial in adrenocortical tumors and tumors with FGFR translocations, amplification, and mutations. ARQ 087 is a potent FGFR (Fibroblast Growth Factor Receptor) inhibitor. Also, in March 2018, the University of Colorado Anschutz Medical Campus presented novel models to recognize genetic targets and test promising treatments in adrenocortical carcinoma at the ENDO Conference exploring a new therapeutic option.

Access Report @ https://www.marketresearchfuture.com/reports/adrenocortical-carcinoma-treatment-market-6567

The global adrenocortical carcinoma treatment market has been segmented into type, therapy, and end-user.

Some of the key players in the global adrenocortical carcinoma market are Pfizer Ltd., Arqule, EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO. ,Ltd., Hitachi, Ltd., NeuroLogica Corp., and Digirad Corporation.

Chronic Obstructive Pulmonary Disease Market Size Industry Insights, Top Trends, Drivers, Growth and Forecast to 2023

Chronic Obstructive Pulmonary Disease Market

Due to the unhealthy lifestyle among people in consumerist cultures, pollution, and various reasons, the number of people suffering from respiratory disorders and chronic diseases is rising. Among these, a common one is a chronic obstructive pulmonary disease (COPD). This obstructive lung disease characterized by long-term breathing problems and poor airflow. When a disease becomes common, and the number of people suffering from it goes up, so does the market offering treatment for it. The major factor driving the growth of market COPD treatment is the increasing number of adult smokers. Due to environmental pollution, the number of rapidly growing asthma patients is increasing the growth of the COPD market.

Market Research Future (MRFR) has published a research report about the global chronic obstructive pulmonary disease (COPD) market that measures huge elevation in this market between 2016 and 2022. This report provides a detailed analysis of market structure with the forecast for next years and provides insights into factors affecting the market growth. Analyzing the market on the basis of various factors, it evaluates the market with current market size and future potential regarding growth. Profiling various key players in the market, the report discusses their activities and observes competitive developments like joint ventures, mergers and acquisitions, new product developments, strategic alliances, and research and developments (R & D).

The global chronic obstructive pulmonary disease market has been segmented into medicines, treatments, types, and lastly region. On the basis of medicines, this market has been segmented into antibiotics, bronchodilators, combination inhalers, inhaled steroids, oral steroids, phosphodiesterase-4 inhibitors, and theophylline. Antibiotics are useful for fighting bacterial infections. Bronchodilators are medications that open (dilate) the airways (bronchial tubes) of the lung by relaxing bronchial muscles. They allow people with difficulty in breathing to breathe better. A combination inhaler combines two kinds of medicine in one device. Usually, in a combination inhaler, one medicine is corticosteroid while the other is a bronchodilator. Advair Diskus, Breo, Dulera, and Symbicort are some examples of combination inhalers. Some examples of inhaled steroids include Arnuity Ellipta, Flovent, Pulmicort, Qvar, and Symbicort are some examples of inhaled steroids. Oral steroids are the non-narcotic type of powerful prescription medication. Commonly called as a PDE4 inhibitor, phosphodiesterase type 4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4).

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/1612

The treatment-based segmentation of market comprises of oxygen therapy, lung transplant, bullectomy and others. Bullectomy is the surgical process for the removal of a bulla, which is a dilated air space in the lung parenchyma. A bulla measures more than 1 cm. Bulla that occupies more than 30% of the hemithorax is called giant bulla. Bulla is the most common cause of COPD. In oxygen therapy, oxygen is used for medical treatment. Lung transplant is a medical process where a permanently damaged lung of a patient is removed, and a healthy lung from another person is planted into the body of the patient. By types, the global COPD market has been segmented into chronic bronchitis and emphysema. Chronic Bronchitis (CB) is defined as a chronic cough and sputum production for at least 3 months a year for 2 consecutive years. Emphysema is a lung condition that causes shortness of breath.

The regional segmentation of global chronic obstructive pulmonary disease market covers The Americas (North America & South Americas), Europe, Asia Pacific, and Middle East & Africa (MEA). Among the Americas, North America is the bigger market for COPD, than South America due to advanced medical facilities and more investment in this region, the biggest local markets are the United States of America (USA) and Canada. North America is the largest market among all regional markets.

Due to the reasons same as the Americas, Western Europe is the bigger market, than Eastern Europe. Although the market in whole Europe is decent and steady in Western Europe, the cream of Europe market in France, Germany, Italy, Spain, and the United Kingdom (UK). Europe is the second largest market for COPD.

In the Asia Pacific region, the market is growing due to the high density of population and improving medical facilities in some countries of this region. During the forecast period, Asia Pacific is expected to be the fastest growing market for COPD. The biggest markets in the Asia Pacific are Australia, China, India, Japan, and South Korea, followed by the rest of the Asia Pacific. In the MEA region, the market is small due to poor or limited infrastructure and less investment in health care. However, due to hookah smoking, the number of people suffering from COPD is sizable. In this region, the biggest markets are Kuwait, Oman, Saudi Arabia, United Arab Emirates (UAE) and Qatar.

Access Report @ https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612

Key Players

The key players in global COPD market are Abbott (USA), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), F. Hoffmann-La Roche Ltd (Switzerland), GSK (UK), Merck (USA), Novartis AG (Switzerland), and Pfizer Inc (USA).

Bone Wax Market Size, Analytical Overview, Growth Factors, Demand and Trends Forecast to 2023

Market Highlights

Bone wax is a mechanical hemostat used in surgeries to stop bleeding. Bone wax does not involve any pharmacological action. It is basically a sterilized mixture of beeswax and it consists of isopropyl palmitate, which is a wax softening agent and is used to stop bleeding from the bone surface. It is used in surgical procedures like orthopedics, thoracic surgery, neurosurgery, dental, oral, traumatology, and jaw surgery. The rising number of surgical procedures is a major booster which drives the global bone wax market. Orthopedic surgeries are increasing due to the rising prevalence of orthopedic diseases, especially osteoporosis and accidental fractures. Also, the rising usage of absorbable bone wax products and the growing geriatric population is also fueling the market growth. According to the Population Reference Bureau in 2016, the number of Americans aged 65 and older is projected to reach 98 million by 2060. On the other hand, stringent government rules for the approval of bone wax and the availability of alternatives for bone wax may hinder the growth of the market during the forecast period.

The global bone wax market is currently dominated by many market players. The prominent market players are engaged in new product launches and strategic partnerships to strengthen its market position. For instance, in February 2016, Wound Management Technologies announced the US Food and Drug Administration (FDA) clearance for its product HemaQuell, which is a resorbable bone wax.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/6463

Regional Analysis

The market in the Americas is expected to dominate the global bone wax market during the forecast period owing to the increasing awareness among the people regarding bone wax and rising orthopedic surgeries. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, increasing prevalence of bone diseases, and growing number of accident and injuries. According to the Arthritis Research UK in 2016, around 10 million people in the UK had a form of arthritis. Moreover, the market in Asia-Pacific region is anticipated to be the fastest-growing during the assessment period owing to the increasing awareness about surgical procedures requiring bone wax, increasing geriatric population, and rising healthcare expenditure. The market in the Middle East & Africa is likely to account for the smallest share of the global bone wax market due to the slowly growing healthcare infrastructure mainly in the African region.

Segmentation

The global bone wax market has been segmented into product, material, application, and end user.

The market, on the basis of product, has been segmented into absorbable bone wax and non-absorbable bone wax.

The market, by material, has been segmented into natural bone wax and synthetic bone wax.

The market, by applications, has been segmented into neurosurgery, orthopedic surgery, thoracic surgery, oral surgery, and others.

The market, by end-users, has been segmented into hospitals, specialty clinics, ambulatory surgical centers, and others.

Access Report @  https://www.marketresearchfuture.com/reports/bone-wax-market-6463

Key Players

Some of the key players in the global bone wax market are ABYRX Inc., Wound Management Technologies Inc., Aesculap Inc., Ethicon Inc., Medtronic plc, Baxter International, Medline Industries Inc., Futura Surgicare Pvt. Ltd., CP Medical Corp., Bentley Healthcare Pvt. Ltd.,  WNDM Medical Inc., GPC Medical Ltd., and others.

Arthroscopy Instrument Market : Key Players, Growth, Analysis by 2019 – 2023

Market Highlights

A number of factors such as increasing preference for minimally invasive procedures, ongoing technological advancements, and improving regulatory framework are fueling the growth of the global arthroscopy instrument market. Additionally, increasing occurrences of sports-related musculoskeletal disorders, such as the bone tumor, rheumatoid arthritis, and osteoarthritis, are propelling the growth of this market. The world health organization predicts the prevalence of rheumatoid arthritis to be between 0.3% and 1% and more common in women and developed countries. Moreover, the prediction also states that 9.6% of men and 18.0% of women aged over 60 years have osteoarthritis.

However, the high cost of arthroscopy instruments, reimbursement challenges in the medical device industry, and poor healthcare system in low and middle-income countries may hamper the growth of the market. For instance, as per the National Center for Health Statistics, in the United States, an approximate 650,000 arthroscopic lavage and debridement procedures are performed for knee pain each year, at an average cost of USD 5,000 each.

It is estimated that the global arthroscopy instrument market is expected to grow at a CAGR 6.5% during the forecast period of 2018–2023.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/6068

Regional Analysis

The Americas dominates the global arthroscopy instrument market owing to the presence of major market players, the high adoption rate of minimally invasive devices, and increasing incidences of joint-related diseases boost the market growth in this region. Further, according to the American Orthopedic Society for Sports Medicine, in the United States, an estimated 4 million people undergo knee arthroscopies, whereas the number of patients undergoing shoulder arthroscopies is 1.4 million per annum. Furthermore, rising cases in arthroscopic surgeries along with rising population awareness regarding health are driving the growth of the arthroscopy instruments market.

Europe holds the second position in the global arthroscopy instrument market. It is expected that the government support towards research & development expenditure and rising prevalence bone disorders is likely to drive the European market.  According to the Arthritis Research U.K. in 2016, around 10 million people in the U.K. have a form of arthritis. Moreover, it was estimated that over 86,000 hip and over 90,000 knee replacements take place every year.

Asia Pacific is the fastest growing in the global arthroscopy instruments market owing to a huge patient pool, increasing demand for minimally invasive surgeries, and development in healthcare technology. According to Osteoporosis Australia, around 4.74 million Australians over 50 years of age are suffering from either osteoporosis or poor bone health. Which further fuels the need for arthroscopy surgeries. Healthcare expenditure is found to be improving in various Healthcare expenditure is found to be improving in various Asia Pacific regions. Moreover, the availability of skilled physicians and nurse practitioners and the low cost of surgeries have fueled medical tourism in India.

The Middle East and Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.

Access Report @ https://www.marketresearchfuture.com/reports/arthroscopy-instruments-market-6068

Segmentation

The global arthroscopy instrument market is segmented on the basis of the product, application, and end-user.

On the basis of product, the market is classified into arthroscope, arthroscopic implants, fluid management systems, visualization systems, radiofrequency system, power shavers and others. The arthroscopic implants are further segmented as knee implants, hip implants, shoulder implants, and others. The radiofrequency systems are further segmented as RF generators, RF probes, and wands and footswitch.

On the basis of application, the market is segmented knee arthroscopy, hip arthroscopy, spine arthroscopy, foot and ankle arthroscopy, shoulder arthroscopy, and others.

On the basis of end-user, the market is segmented into hospitals, ambulatory surgical centers, and others.

Key Players

Some of key the players in the global arthroscopy instrument  market Smith & Nephew (U.K.), Arthex (U.S.), DePuy Synthes (U.S.), Stryker (U.S.), Conmed (U.S.), Medtronic, Inc. (U.S.), Zimmer Biomet (U.S.), B. Braun (Germany), Olympus (Japan), Karl Storz (Germany), Richard Wolf  (Germany), Medicon (Germany), Sklar (U.S.), GPC Medical (India), and Millennium (U.S.).

Global Practice Analytics Market 2019-2023 | Size, Share, Trends, In-Depth Analysis, Segmentation, Drivers and Top Key Players

Market Highlights

Practice analytics is one of the effective tools, used for keeping records and analysis of data that are collected. Increasing use of internet and more and more information going online, are together creating an easy way for analysis. Increasing small and mid-sized healthcare firms will directly increase the growth of this market. Educating and creating initiatives about digitalization in software based analysis methods also leads to the growth of this market. Moreover, initial cost of software which is used and technically easy way to support the data and summaries is low and increasing demand for IT departments in healthcare industry will increase the growth of the market.

 However, all personal data stored online and accessible through internet may hinder the growth of this market.  

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/1017  

Segmentation

Global practice analytics market is segmented on the basis of its module type and application. On the basis of module type, it is segmented into clinical module, front office module, and business module. On the basis of application, it is segmented into standard reports, graphical user interface design, SQL database and others.

Regional Analysis

On regional basis, this market is segmented into America, Europe, Asia Pacific & Middle East and Africa. America dominates a major share of this market as government is backing more research and development in the information technology sector. Recent advances in IT and its numerous uses in healthcare domain has boosted the growth of this market. Europe accounts for the second largest market owing to increasing research and development and well-established healthcare sector. Asia Pacific is the fastest growing market due to the presence of huge opportunities in the market and the continuously increasing demand for better healthcare software’s. However, the Middle East & Africa has the least market share due to not much developed healthcare industry.

Access Report Details @ https://www.marketresearchfuture.com/reports/practice-analytics-market-1017

Among numerous players, top players of the global practice analytics market are Accenture (US), AGS Health, Inc. (India), Practice Analytics (US), Greenway Health, LLC (US), MediSys (US), Cardinal Health (US), McKesson Corporation (US), Harris digiChart (US), Meditab (US), UroGPO  (US), Global Health Management Services (US), IBM and KNIME (Switzerland).

Accenture is one of the leading health care solution providers. It provides health insights, healthcare data management and analysis. Additionally, the company operates in three major domain which includes digital health, operational transformation and health consumerism. Accenture developed robotics process automation for operational improvements of health insurance domain.

 AGS health is one of the leading provider of medical billing, medical coding and business analytics services in leading healthcare domain. Moreover, it has tie ups with blue chip users, which includes large health systems & hospital corporations, physician groups, academic medical centers, billing companies, revenue cycle management companies, coding companies and providers of other healthcare services.

Leuprolide Acetate Market size by Industry Insight Analysis, Segments, Top Key Players, Drivers and Trends to 2023

Global Leuprolide Acetate Market - Overview

Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone names as Lupron. There are various uses of Lupron include the treatment of endometriosis, breast cancer and prostate cancer. It is one of the on important medicines and is the WHO Model List of, essential medical required in a fundamental well-being system.

The global Leuprolide Acetate market is expected to grow at a steady growth during the forecast period 2017-2023. The major factor increasing the growth of the market include increasing prevalence of Prostate cancer among individuals especially with aged individuals. Moreover, breast cancer has been a key market driver for the leuprolide market globally. Increasing use of leuprolide for the purpose of endometriosis treatment has fuelled the growth of the market. Between the ages of 15 and 44 women, endometriosis is affected to one or more in ten women in the United States, leading to pelvic discomfort and infertility, production loss and poor quality of life. The demand for leuprolide in veterinary treatment is another factor which adds to the growth of leuprolide acetate market.

The market is forecasted to demonstrate a steady growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017–2023.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/785

Global Leuprolide Acetate Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of leuprolide acetate appears to be highly competitive and fragmented. With well-established market in the North America and European region with major companies having their home in the regions and generating maximum market share. These companies have expanded their operating unit in various other emerging regions as well. Moreover the other small and medium scale players are generating revenue from local market.

With top selling cancer products, Takeda and AbbVie account for the major market share for the leuprolide acetate market across the globe. Although there are various other companies involved in the development of the product.   Myovant Sciences a Switzerland based company involved in the development of new drug that may be able to cure both women’s health disorders and prostate cancer. Myovant with its new product relugolix has a diverse mechanism of action that that of AbbVie's Lupron Depot, letting it work faster, while the therapy is presently in last-stage of its development, with data predicted in 2019.

Access Report @ https://www.marketresearchfuture.com/reports/leuprolide-acetate-market-785

Global Leuprolide Acetate Market - Regional Analysis

The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.

North America accounted for the largest market share. The major factor influencing the growth of the market include increasing aging population that is key factor which will drive the demand for leuprolide acetate market in this region. Furthermore, huge investment in Research and development and advancement of new techniques has caused in better care for the patients and understanding for the medical professionals. Increase medical professionals has resulted in demand for better standards and quality end products which will further influence the demand in the leuprolide acetate market in the North American region.

Europe accounted for the second largest market share for global leuprolide acetate market. According study published by World Cancer Research fund, Europe accounted for the largest number of individuals suffering from prone to prostate and breast cancer influencing the European market for leuprolide acetate. Moreover, rising number of cancer patients in the region, and steady growth in the number of medical professionals in significantly contributes to the growth of the European leuprolide market. Adding to this constant focus on novelty and strict government regulations make sure high quality of products delivered to the end users which further influence the growth of European market.

Asia pacific expect to be fastest growing market due to raising of funds for research and development activities, and growing government initiatives for the awareness and preventive cancer. Particularly, India and China are anticipated to be a growing and the fastest growing market due to improvement in healthcare domain and increasing prevalence of cancer related diseases. Many major players seeking opportunity and expand their presence in this region influencing the growth of the market.   

The Middle East & Africa holds the least share in the Leuprolide Acetate market due to lack of awareness, less emphasis on research and development activities, and poor medical facilities.

Flexible and Semi-rigid Ureteroscopy Market : Key Players, Growth, Analysis by 2019 – 2023

Key Players

Some of the key players in the global flexible and semi-rigid ureteroscopy market are Stryker (US), Olympus Corporation (Japan), Boston Scientific (US), Richard Wolf (Germany), KARL STORZ (Switzerland), ELMED Medical Systems (Turkey), Maxer Endoscopy (Germany), Rocamed (France), Vimex Endoscopy (Poland), ProSurg (US), and others.

Market Highlights

The flexible and semi-rigid ureteroscopy market is expected to witness tremendous growth owing to the rising prevalence of kidney cancer, kidney stone, and change in lifestyle. Other key factors such as the growing consumption of alcohol, change to sedentary lifestyle, increasing dehydration, and obesity are contributing towards the growth of the market. According to the University Hospital Southampton NHS Foundation Trust, March 2016, the prevalence of renal stone treatment increased between 5 to 10% with a 75% increase in obese patients. However, factors such as high cost of ureteroscopy procedures are expected to hinder the market growth during the forecast period.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/6469

Segmentation

The global flexible and semi-rigid ureteroscopy market is segmented on the basis of product, application, and end-user. The flexible and semi-rigid ureteroscopy market, by product, is categorized into flexible ureteroscopes, semi-rigid ureteroscopes, and rigid ureteroscopes. Flexible ureteroscopes are further segmented into fiberoptic ureteroscopes and digital ureteroscopes. On the basis of application, the market is segmented into therapeutic applications and diagnostic applications. Therapeutic applications are further segmented into urinary stricture, urolithiasis, and kidney cancer. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, ambulatory surgical centers, research centers, and others.